The drugmaker’s current diagnostics chief Thomas Schinecker will take over as CEO in March, while Schwan will seek election as chair of Roche’s board.

On the company’s latest earnings call, analysts pressed for more details about the drug, called lecanemab, including its odds for approval and how that could reshape Biogen.

Health officials argue a new type of shot could help to persuade unvaccinated people, although some surveys suggest that might not be the case. 

The cuts are meant to conserve cash as the biotech attempts to position its coronavirus vaccine as a potential booster.

The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments. 

The cancer drugmaker, which was formed in early 2017 by a group that includes Nobel Prize winner David Baltimore, is one of dozens of biotechs to cut staff this year. 

The setback slows plans to broaden use of a drug that analysts expect to generate nearly $10 billion in annual sales later this decade.  

The cream, known as Opzelura, is now the only treatment approved in the U.S. to repigment skin in patients with the most common form of vitiligo.

The pharmaceutical company is considering selling or splitting off its struggling Sandoz division and expects to give an update by the end of the year.

The California biotech is exercising its option to acquire GeneTx BioTherapeutics for $75 million after seeing data from the companies’ study of an Angelman syndrome treatment.

Second quarter reports could bring questions on a reportedly forthcoming $40 billion takeover, GSK’s new slimmed-down look and market uptake for expected blockbusters-to-be from Lilly and Bristol Myers.

The food giant will pay French company Enterome about $40 million to join in the development of an inflammatory bowel disease drug as well as other food allergy treatments.